TY - JOUR T1 - Dr. Wiland, <em>et al,</em> reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 259 LP - 259 DO - 10.3899/jrheum.161405 VL - 44 IS - 2 AU - PIOTR WILAND AU - JEAN DUDLER AU - DOUGLAS VEALE AU - HASAN TAHIR AU - RON PEDERSEN AU - JACK BUKOWSKI AU - BONNIE VLAHOS AU - THERESA WILLIAMS AU - STEFANIE GAYLORD AU - SAMEER KOTAK Y1 - 2017/02/01 UR - http://www.jrheum.org/content/44/2/259.2.abstract N2 - To the Editor:We thank Prof. Bannwarth for his insight into the potential influence of methotrexate (MTX) dosing in the PRIZE clinical trial1. The objective of the PRIZE study was to compare sustained remission rates after 39 weeks of reduced medication in patients with rheumatoid arthritis who had first achieved remission after 52 weeks’ treatment with a combination of etanercept (ETN), 50 mg subcutaneously (SC) once a week, and MTX, orally 10–25 mg once a … Address correspondence to Prof. P. Wiland, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland. E-mail: pwiland1{at}gmail.com ER -